Samsung Biologics Co. (207940.KS): Asia Healthcare CDMO Day 2026 Key Takeaways: Announcement of client orders and plant 6 capex as key

Goldman Sachs hosted Samsung Biologics (207940.KS) at the Asia Healthcare CDMO Day 2026 (presenters: IR). Bottom line: management highlighted Samsung Biologics' core competitive advantage in speed-to-market, underpinned by its build-ahead capacity strategy, while outlining expansion plans across capacity, modality and geography. Key near-term catalysts remain the formal announcement of Plant 6 and associated capex, which management stated could occur within 2026, alongside continued order momentum driven by biologic outsourcing demand and supply chain diversification. Speed-to-market remains the key differentiator: the company's primary advantage is industry-leading speed-to-market on top of a 99% batch success rate, attributed to proactive capacity investments and industry-leading construction timelines. Plant 5 (180kL) was completed in 24 months versus an industry norm of 3.5-4 years for construction alone;